Last reviewed · How we verify
Tetrathiomolybdate
Tetrathiomolybdate is a Small molecule drug developed by Dartmouth-Hitchcock Medical Center. It is currently in Phase 3 development. Also known as: TM.
Tetrathiomolybdate is a small molecule with the chemical name ammonium tetrathiomolybdate, used as a building block in bioinorganic chemistry. It is also known as a drug for the treatment of Wilson's disease, and has been studied in clinical trials for various conditions including psoriasis, melanoma, and idiopathic pulmonary fibrosis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Tetrathiomolybdate |
|---|---|
| Also known as | TM |
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Study of Tetrathiomolybdate (TM) Plus Capecitabine (PHASE1, PHASE2)
- Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer (PHASE2)
- Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 (PHASE2)
- Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease (PHASE3)
- Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants (PHASE1)
- Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. (PHASE1)
- A Study of the Cardiac Effects of ALXN1840 in Healthy Adults (PHASE1)
- Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetrathiomolybdate CI brief — competitive landscape report
- Tetrathiomolybdate updates RSS · CI watch RSS
- Dartmouth-Hitchcock Medical Center portfolio CI
Frequently asked questions about Tetrathiomolybdate
What is Tetrathiomolybdate?
Who makes Tetrathiomolybdate?
Is Tetrathiomolybdate also known as anything else?
What development phase is Tetrathiomolybdate in?
Related
- Manufacturer: Dartmouth-Hitchcock Medical Center — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: TM
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing